Streetbeat News

Equity Actions

TSM

A significant bullish stance has been taken on Taiwan Semiconductor (NYSE:TSM) by a large investor or institution, as indicated by unusual options activity. The sentiment among these big-money traders is split 50% bullish and 50% bearish. The targeted price range for TSM over the last 3 months is between $90.0 and $155.0. Needham and Susquehanna have maintained their Buy and Positive ratings on TSM respectively, with price targets of $115 and $135.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:32 am

ACT

Enact Holdings, Inc. (NASDAQ:ACT) has announced a new share repurchase program with authorization to purchase up to $100 million of its common stock. This is in addition to the company's current $75 million share repurchase program, under which it has repurchased approximately $71 million of shares to date. The timing and amount of any share repurchases will be opportunistic and will depend on a variety of factors.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 10:31 am

AIZ

Assurant Inc. (AIZ) has announced plans to continue its share repurchase activity for the remainder of the year. This move is expected to provide a return to shareholders and potentially increase the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:31 am

BLKB

Blackbaud has reiterated its 2023 full year financial guidance, expecting non-GAAP revenue of $1.095 billion to $1.125 billion, non-GAAP adjusted EBITDA margin of 30.5% to 31.5%, and non-GAAP earnings per share of $3.63 to $3.94. The company also expects non-GAAP adjusted free cash flow of $190 million to $210 million. The guidance includes assumptions such as an expected non-GAAP annualized effective tax rate of approximately 20% and capital expenditures in the range of approximately $65 million to $75 million.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 10:30 am

TEX

Terex Corporation has raised its FY23 outlook, with EPS now expected to be around $7.00, up from the previous range of $5.60-$6.00, and beating estimates of $6.02. The company also increased its revenue forecast from $4.8B-$5B to approximately $5.1B, surpassing estimates of $4.94B.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 10:29 am

PLTR

A significant amount of unusual options activity has been detected for Palantir Technologies (NYSE:PLTR), with a bearish stance being taken by a 'whale' investor. Of the 58 strange trades detected, 46% were bullish and 53% were bearish. The total amount for puts was $744,163 and for calls was $2,224,566. Whales have been targeting a price range from $3.0 to $42.0 for Palantir over the last 3 months. The current price of PLTR is up 0.76% at $19.99. Wedbush has downgraded its action to Outperform with a price target of $25.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:28 am

FBRX

Forte Biosciences, Inc. has announced a $25 million financing to support the advancement of FB-102.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:28 am

SCI

Service Corporation International (SCI) has revised its FY23 EPS guidance to $3.40-$3.60 from $3.45-$3.75 due to the inflationary environment and higher than expected interest rates. The company also raised its adjusted operating cash flow guidance to $830 million to $880 million from $740 million to $800 million, reflecting strong operating cash flow and an expected decrease in cash taxes due to a change in tax accounting method.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:23 am

SE

A whale investor has taken a bullish stance on Sea (NYSE:SE), with 71% of the investors opening trades with bullish expectations and 28% with bearish. The trades include 2 puts for a total amount of $425,800 and 12 calls for a total amount of $720,288. The price target for Sea over the last 3 months ranges from $45.0 to $105.0. UBS has upgraded its action to Buy with a price target of $86.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:23 am

CVS

A significant bullish stance has been taken on CVS Health (NYSE:CVS) by a large investor, as indicated by unusual options trading activity. The sentiment among these big-money traders is 71% bullish and 28% bearish. The targeted price range for CVS Health over the last 3 months is from $35.0 to $90.0. Analysts from JP Morgan, Barclays, and Mizuho have maintained their positive ratings on CVS Health, with price targets of $106, $89, and $88 respectively.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:22 am